Response to Letter to the Editor entitled "Methodological considerations in assessing the clinical impact of TP53 classifications in advanced NSCLC".

Zhou DD; Lee CK

doi:10.1016/j.lungcan.2026.109303

← 뒤로

Response to Letter to the Editor entitled "Methodological considerations in assessing the clinical impact of TP53 classifications in advanced NSCLC".

사설/논평 0/5 보강

Lung cancer (Amsterdam, Netherlands) 2026 Vol.214() p. 109303

Zhou DD, Lee CK

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

↓ .bib ↓ .ris

APA Zhou DD, Lee CK (2026). Response to Letter to the Editor entitled "Methodological considerations in assessing the clinical impact of TP53 classifications in advanced NSCLC".. Lung cancer (Amsterdam, Netherlands), 214, 109303. https://doi.org/10.1016/j.lungcan.2026.109303

MLA Zhou DD, et al.. "Response to Letter to the Editor entitled "Methodological considerations in assessing the clinical impact of TP53 classifications in advanced NSCLC".." Lung cancer (Amsterdam, Netherlands), vol. 214, 2026, pp. 109303.

PMID 41679016

DOI 10.1016/j.lungcan.2026.109303

같은 제1저자의 인용 많은 논문 (1)

Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials.
Lung cancer (Amsterdam, Netherlands) 2026